HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Jun.10) - Medical Service Price Reform, Medical Device CXO, Lockdown Lifted

China Healthcare Weekly (Jun.17)- Digital Healthcare New Policy,mRNA Dilemma, Drug Supply Disruption

China Healthcare Weekly (Jun.24)-7th National VBP, Online Pharmacy New Policy, OK Lens Rules Relaxed

China Healthcare Weekly (Apr.29)-SH Lockdown Impact on Pharma/CXO,China Biotech Categories & Way Out

China Healthcare Weekly (May.27) - New TAVR Policy, Exiting Issue of COVID Testing, RemeGen/Keymed

China Healthcare Weekly (May20)-Lockdown Impact on Macro Economy, Bottom Signal? Rare Disease Policy

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>The blood products VBP results in Guangdong relieved the worries of the market, which provides us with a stable policy environment. Investors would have more confidence in this industry.</li>
<li>Higher burn/market cap ratio would force biotech to dilute larger portion of shares to raise money. Companies with solid R&amp;D may also die due to financing gap in market downturn.</li>
<li>The high market value not commensurate with the real industry development level has been formed.So, in the industry clearing process, there's more bubble in market value needs to be digested. </li>
</ul>


The blood products VBP results in Guangdong relieved the worries of the market, which provides us with a stable policy environment. Investors would have more confidence in this industry.
Higher burn/market cap ratio would force biotech to dilute larger portion of shares to raise money. Companies with solid R&amp;D may also die due to financing gap in market downturn.
The high market value not commensurate with the real industry development level has been formed.So, in the industry clearing process, there's more bubble in market value needs to be digested. 


China Healthcare Weekly (Jun.3) - Blood Products VBP, Burn/Market Cap Ratio, Longer Recovery Cycle